Tevogen Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tevogen Inc. on September 14, 2026. The filing discloses the grant of Restricted Stock Awards (RSAs) to the Company's executive officers under the Tevogen Inc. 2024 Omnibus Incentive Plan. The Company is incorporated in Delaware and its common stock (TVGN) and warrants (TVGNW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements rather than financial performance results.
Material Changes and Executive Compensation
On September 14, 2026, the Company granted the following Restricted Stock Awards:
- Ryan Saadi (CEO and Chairperson): 8,000,000 Restricted Shares.
- Kirti Desai (CFO): 750,000 Restricted Shares.
As of immediately following the grant, Dr. Saadi owned 74.4% and Mr. Desai owned 6.3% of the 15,736,540 outstanding shares of Common Stock.
Performance Conditions and Risks
Vesting Conditions: The Restricted Shares vest only upon the Board's certification that the Company achieves $1.0 billion in aggregate revenue by September 30, 2031. Until vesting, shares cannot be sold or transferred, though grantees retain voting rights.
Forfeiture Risks: The awards are subject to forfeiture under the following conditions:
- Failure to meet the $1.0 billion revenue threshold by the end of the performance period.
- Termination of service prior to vesting.
- Attempted transfer of shares prior to vesting.
- Change in Control where shares are not assumed or continued.
- Conduct Detrimental to the Company: Includes serious misconduct, breach of agreements, or competitive activities. This may trigger forfeiture of unvested shares and a clawback of proceeds from previously sold shares or the fair market value of owned shares.
Investor Verification Checklist
- Verify the specific definition of "aggregate revenue" in the RSA Agreement (Exhibit 10.1) to understand accounting treatment for the $1.0 billion threshold.
- Review the Company's current revenue trajectory to assess the feasibility of the 2031 performance target.
- Confirm the total outstanding share count and the dilutive impact of the 8.75 million new restricted shares if the performance target is met.
- Examine the "Conduct Detrimental" clause details in the full RSA Agreement to understand the scope of potential clawbacks.